Currently in phase III clinical trials, Rovalpituzumab tesirine (Rova-T; SC16LD6.5) is a biomarker-specific ADC for the exclusive targeting small-cell lung cancers expressing Delta-like protein 3 (DLL3) antigen [96]. The gene discussed is DLL3; the disease is small cell lung carcinoma.